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1. Introduction 
The leishmaniasis is a group of diseases caused by protozoan haemoflagelates of the genus 
Leishmania1,2. These parasites belong to the family of the Trypanosomatidae (order 
Kinetoplastida) and are closely related to the Trypanosomes3. Despite enormous efforts, it has 
proved difficult to predict the exact scale of the impact of leishmaniasis on public health, 
since many cases remain unreported or misdiagnosed4. It is estimated that approximately 12 
million people are currently infected and a further 367 million are at risk of acquiring 
leishmaniasis in 88 countries, 72 of which are developing countries and 13 of them are 
among the least developed in the world1, 4. Hence we can link leishmaniasis to poverty, 
economic development and various environmental changes such as deforestation, 
urbanization, migration of people into endemic areas and building of damns etc5. The 
annual incidence rate is estimated to be 1 to 1.5 million cases of cutaneous leishmaniasis 
(CL) and 5,00,000 cases of visceral leishmaniasis (VL); these are the two major clinical types 
of leishmaniasis6. The only proven vector of the Leishmania parasite is the blood-sucking 
female sandfly1, 7 of the genus Phlebotomus in the old world and Lutzomyia in the new world8. 
The insects are 2-3 mm long (one-third the size of typical mosquitoes) and are found 
throughout the tropical and temperate parts of the world. The sandfly larvae require organic 
matter, heat and humidity for development and so are commonly found in house-hold 
rubbish, burrows of old trees and in cracks in house walls9. The sand flies usually feed at 
night while the host is asleep10. There are five most important Leishmania species namely L. 
tropica, L. major, L. donovani, L. braziliensis braszliensis, L. b. peruviensis and L. mexicana which 
cause the three forms of the disease dermal CL (oriental sore), VL and mucocutaneous 
leishmaniasis (Chiclero's diseases and Espundi)11, 12, 13.  Leishmania exhibits a dimorphic life 
cycle14 involving two life-cycle stages, the elongated promastigote with free flagellum 
present in the insect and the intracellular amastigote form15. 
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VL, commonly known as kala azar, is characterized by irregular bouts of fever, substantial 
weight loss, swelling of the spleen and liver, and anaemia (occasionally serious)16. VL was 
first described in 1903, by Dr. William Boog Leishman17, 18, 19, an English military surgeon 
and Dr. Charles Donovan17, 20, an Irish physician by identifying the parasites in spleen 
smears of a patient died of “Dum-Dum fever” i.e. a low degree of fever with 
hepatosplenomegaly and severe progressive cachexia (wasting), swollen lymph glands, 
leucopeania, thrombocytopaenia with relative monocytosis and loss of hair18, 20. These 
physicians reported the existence of the parasite for visceral leishmaniasis and so the 
causative agent acquired the name as Leishmania donovani21. This is not to say that 
leishmaniasis did not exist before 1903, on the contrary. Archibadi in 1922 described an 
epidemic of Kala-azar, which occurred in the Garo hills of Assam22 and in Saudi Arabia23, 24 
as far back as 1870. Cunningham recorded a similar disease that occurred in 1885, caused by 
a parasite25, which was later named Leishmania tropica, the causative agent of CL26. Nicolle in 
1908 reported that mammals including dogs could act as reservoir hosts for the Leishmania 
parasite27. Swaminath et al in 1942, proved using human volunteers that the Leishmania 
parasite could be transmitted by the phlebotomus sandflies28. 
If left untreated, the fatality rate of VL in developing countries can be as high as 100% 
within 2 years. The recommended drugs for VL are the pentavalent antimonials sodium 
stibogluconate  (Pentostam) and Meglumine Antimoniate (Glucantime)29. Both drugs have 
been used for over 50 years, and they require long courses of parenteral administration. The 
treatment has traditionally been unsatisfactory because of drug toxicities, poor responses, 
multiple disease syndromes and other factors including the recent emergence of antimony-
resistant strains30. Side effects of sodium stibo gluconate (SAG) include changes in liver 
function, biochemical pancreatitis, electrocardiogram (EKG) changes, musculoskeletal 
symptoms, thromboctopenia etc. Alternative treatments for VL include the polyene 
antibiotic amphotericin B31 that constitute highly effective, less toxic lipid formulations32, 33. 
In regions of India where there is a high frequency of resistance to antimony, amphotericin 
B in a dose of 15-20 mg/kg, body wt is administered intravenously (IV) over a period of 30-
40 days34. Recently several compounds of herbal origin have been reported to have potency 
against VL35, 36, 37.  
Post Kala azar dermal leishmaniasis (PKDL) occurs in India and mainly in Sudan and Kenya 
in Africa38. Reports of PKDL in China, Iraq and Nepal have also been documented 39,40. In 
the new world PKDL is extremely rare41. Usually PKDL follows recovery from a Kala azar 
infection, though less commonly, it has been known to occur in patients who have not 
suffered previously from Kala azar42. Both the Indian and the African PKDL display similar 
symptoms. The disease begins with small measles-like lesions (hypopigmented macules, 
papules or nodules) appearing on the face, and gradually increase in size. Eventually the 
lesions spread to the upper trunk, arms, forearms, thighs, legs, abdomen, the neck and the 
back. The multiple lesions can coalesce to form larger lesions and can lead to the gross 
enlargement of facial features such as the nose and lips, giving an appearance similar to 
leprosy. The disease is particularly severe if the lesions spread to the mucosal surfaces of the 
nasal septum, hard and soft palate, oropharynx, larynx or the eye lids and the cornea 
leading to blindness43, 44. Potentially the lesions can appear on any part of the body. There 
have been reports of lesions occurring on the glands of the penis and genital mucosa hence 
the possibility of PKDL being transmitted sexually. In addition to the disease being 
confused with leprosy, PKDL can also resemble cutaneous leishmaniasis, secondary 
syphillis and sarcoidosis44. The lesions are usually self-limiting, however those that do not 
www.intechopen.com
Repair of Impaired Host Peroxisomal Properties Cropped Up Due to Visceral Leishmaniasis  
May Lead to Overcome Peroxisome Related Genetic Disorder Which May Develop Later...  335 
heal spontaneously within six months have to be treated45. Pentavalent antimonials remain 
the drugs of choice for treating PKDL. SAG  at a dose of 20 mg/Kg of body weight 
administered intramuscularly for 4-5 months is recommended. In addition Ketoconazole 
and allopurinol can be given orally to improve response. In antimony resistant cases 
amphotericin B is an effective replacement44, 46. The reason for incidence of PKDL is still not 
clear and the evidence is yet to be explored. Several studies indicate that PKDL may develop 
as a result of genetic disorder during the parasitic disease kala azar. Indian PKDL appears 
anything between 1-7 years after apparent cure of Kala azar, although longer periods of 
upto 20-30 years have been reported47 The African form of the disease usually appears 
within a few months after cure, in most cases within 6 months, on average within 56 days. 
However it can develop during the treatment Kala azar, in which case the term Para Kala 
azar dermal leishmaniasis would seem more fitting48. The choice available drug is limited 
and inadequate49. 
Although the geographical distribution of Leishmania infection is restricted to the area of 
distribution of Phlebotomus sandflies, Human immunodeficiency virus (HIV) infection may 
modify the traditional anthroponotic pattern of VL transmission. Very rarely Leishmania 
transmission has been described by alternative means that are also shared by HIV 
transmission, including blood transfusion50 congenital transmissions51, 52, 53 and laboratory 
acquired54. Worldwide, VL mainly occurs in HIV negative individuals more so in paediatric 
patients55.  The association of Leishmania with HIV56 has lead to a significant shift in the age 
of people at risk57, 58, 59.  
In South West Europe, 75 per cent of HIV sero negative and 80-83 per cent of HIV positive 
patients seen with VL were men59, 60.  
Leishmania/HIV co-infection is emerging as a serious new disease pattern and is becoming 
increasingly frequent. Of the 1700 cases of co-infection reported to the World Health 
Organization from 33 countries worldwide up to 1998, 1440 cases were from South-West 
Europe: Spain (835), Italy (229), France (259) and Portugal (117). Of 965 cases retrospectively 
analyzed, 83.2 per cent were males, 85.7 per cent were young adults (20-40 yr) and 71.1 per 
cent were intravenous drug users61.  
Most co-infections in the Americas are reported from Brazil where the incidence of HIV has 
risen from 0.8 cases per 100,000 inhabitants in 1986 to 10.5 cases per 100,000 inhabitants in 
199762. In India, the HIV/Leishmania co-infection has not been extensively studied. The risk 
of visceralization for HIV positive person, infected with Leishmania species typically 
associated with cutaneous disease, is not much of a problem, since VL is several thousand 
times more common than CL in India. However, this may be a very serious issue in the 
Mediterranean countries where CL is very common63. 
A majority of HIV/Leishmania co-infected cases show classical features of VL. These co-
infected patients may also have other features, viz., atypical location due to decreased cell 
mediated immunity (CMI) 64,65, parasitic dissemination to skin, cutaneous and reticulo-
endothelial system (RES), a chronic and a relapsing course, poor drug response and lack of 
anti-leishmanial antibodies.  
The incubation period is variable and may be age related66, 67. Other concomitant 
opportunistic infections are diagnosed in 42-68 per cent of HIV-positive patients68. Fever, 
pancytopenia, hepatosplenolmegaly are common. Classically, splenomegaly may be less in 
HIV positive patients69. Constitutional symptoms (asthenia, anorexia, weight loss etc.) are 
seen in 50-70 per cent of patients and lymphadenopathy in 15-60 per cent of patients. VL 
with HIV infection may present as pyrexia of unknown origin (PUO). Other opportunistic 
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infections like mycobacterial infection, cytomegalovirus (CMV), pneumonias and  Acquired 
immune deficiency syndrome (AIDS) related neoplasms may also occur70, 71. 
Gastrointestinal (GI) symptoms are among the most frequent complaints72, 73, 74. Leishman-
Donovan (LD) bodies have been identified in up to 50 per cent of such patients. The 
commonest site of involvement is the jejunum75, 76. Endoscopy and routine biopsy are 
important tools in the diagnosis. The symptoms may include diarrhoea, malabsorption, and 
hypoalbuminaemia and weight loss. There may be erosive gastro-duodenitis, ulcers and 
colony lesions.  
Cutaneous involvement77 may appear in the skin with Karposi sarcoma, Herpes simplex or 
Zoster. Leishmania may be associated with dermatofibroma, psoriasis, Reiter’s syndrome, 
bacillary angiomatosis, cryptococcosis and oral aphthous ulceration. It may also present as 
dermatomyositis like eruption78, 79. 
Respiratory tract involvement occurs in alveoli and pulmonary septa in 75 per cent of 
patients with VL80. They could present with pulmonary tuberculosis and pneumonia, more 
commonly Pneumocystis carinii pneumonia (PCP). The symptoms could be cough, 
breathlessness, haemoptysis and excessive sputum production. Renal involvement can 
occur. Glomerulonephritis with mild proteinuria, haematuria and even acute renal failure 
have been reported. Tubulointerstitial damage can also occur81.  
Central nervous system (CNS) involvement is very common in the late stages. Pandey et al82 
reported cases in which HIV-Leishmania co-infection was associated with pulmonary 
tuberculosis and tuberculoma in the brain neurocysticercosis and tuberculous meningitis. 
AIDS dementia complex occurs in the late stages and may lead to early death. In such cases, 
cluster of differentiation 4 (CD4) count has been reported to be as low as <50 cells/mm3. 
Pancreatic, pulmonary, pleural, laryngeal, adrenal, pericardial, myocardial and lingual 
leishmaniasis have also been reported. Mucocutaneous leishmaniasis appears in 2-3 per cent 
of VL-HIV co-infected patients83-89. 
Diagnosis is quite difficult as only 40-50 per cent of VL/HIV co-infected cases have a 
positive Leishmania serology90. This percentage is inversely proportional to CD4 cell 
depletion. Anti-Leishmania antibodies in HIV-positive patients are 50 times less than those in 
HIV-negative patients91. Therefore, there may be many false negative tests. The direct 
examination of amastigotes in the splenic and bone marrow aspiration has been the gold 
standard. Detection of Leishmania antigens by Western blot in the urine samples is being 
tried. Polymerase chain reaction (PCR) techniques requiring blood and tissue samples are 
very time consuming92, 93. However, when used in combination with Enzyme-linked 
immunosorbent assay (ELISA) and Direct Agglutination Test (DAT) the results are very 
encouraging. Nested PCR assay has a sensitivity of 95 per cent in the peripheral blood and 
100 per cent in bone marrow/ splenic aspirates94, 95. 
Certain issues are significant in the management of HIV/Leishmania co-infected patients. 
Firstly, optimal duration of treatment is to be given. Secondly, the dose has to be monitored 
and thirdly, there is frequent relapse.  
Sodium antimony gluconate (SAG) has developed resistance and low cure rates of 30-50 per 
cent have been reported32. In such patients, the treatment with SAG has to be given for a 
longer period96.  However, the longer duration of therapy may lead to cardiotoxicity. With 
SAG, there are frequent relapses as seen often in Bihar, India97. Amphotericin B has also 
been tried and response rate of 60 per cent has been observed but 25-60 per cent of the 
patients treated with amphotercin B, are likely to have relapse during the first year after 
completion of treatment98. HIV infected individuals are more likely to suffer from drug 
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related adverse events. In almost all the patients, depending on the CD4 counts (<200/ml) 
Highly Active Antiretoviral Therapy (HAART) can be given99. Amphotericin B can be given 
at a dose of 1 mg/kg for 15 days. Although lipid formulations are less toxic, they are very 
costly 99. Pentamidine is usually not effective and should not be used due to its toxic effects. 
Oral miltefosine100, 101 is a promising alternative at a dose of 2.5 mg/kg for 28 days and has 
been tried by Thakur et al102 in six co-infected patients with good results. Besides treatment 
of VL and administration of HAART, other secondary infections like tuberculosis of the 
chest, oral cadidiasis, CMV infections, Pneumocystis carinii pneumonia (PCP), 
toxoplasmosis, Karposi sarcoma also need to be treated103. 
Peroxisomes104, 105 are the single-membrane bound, catalase containing cytoplasmic 
organelles that contain a fine granular matrix, present in all eukaryotic cells (except the red 
blood cells), including the mammalian host. No such catalase containing subcellular 
organelle is present in the parasitic protozoa Leishmania106  
Peroxisomes were first detected morphologically; their biochemical functions were 
characterized sometimes later. Johannes Rhodin, in 1954, described small organelles (0.5 µm 
in diameter) in mouse kidney cells and identified them as microbodies. Later in 1965, 
Christian de Duve107 proposed the name peroxisomes (as they are peroxide-metabolizing 
organelles), for the distinct organelles isolated by density-gradient centrifugation. These 
organelles contained enzymes for both the production and disposal of hydrogen peroxide 
(H2O2). H2O2 generates reactive oxygen species, which are fatal in all respects. They interact 
with a variety of cellular macromolecules and lead to variety adverse effects like, membrane 
damage (lipid peroxidation), DNA damage (strand breakage), alteration in the protein 
structure (thiol oxidation) and the ultimate consequence may be the loss of cell viability 
(cytotoxicity and cell death) 108. 
Catalase is the marker enzyme for peroxisome as it is the most abundant enzyme within the 
structure109. Active catalase is a heme- containing protein with four identical subunits 
(tetramer). In mammalian liver and kidney cells, peroxisomes are roughly spherical and 
relatively large (0.5 to 1.5 µm in diameter). In other tissues, they are smaller (0.1 µm) and 
known as micro-peroxisomes. In mammalian cell, the average number of peroxisomes is 
approximately 400 that occupy 1% of the total volume of the cell. However, their size, 
number, and enzyme profile vary between different tissues110. In most cases, peroxisomes 
contain dense or granular matrix containing catalase (About 40% of the total peroxisomal 
protein is catalase) and a crystalline core composed of enzyme urate oxidase. Peroxisomes 
have a half-life of about 36 hrs and they divide by fission111. 
The process of formation of peroxisome involves multiple pathways. Lipids must be recruited 
to form the membrane. Lipid composition of the peroxisomal membrane differs from that of 
the total cellular profile112. Peroxisomal proteins (not glycosylated) are synthesized in the 
cytosolic free polyribosomes113 and transported to pre-existing peroxisomes. These include 
both the peroxisomal membrane proteins (PMP) and peroxisomal enzymes114 
The multifunctional structures begin through orchestrated reactions of some proteins, called 
peroxins115. These are the critical processes as their defects leave the cells either devoid of 
peroxisomes or with organelles rendered unable to carry out numerous biochemical and 
metabolic functions attributed to them; such failings often cause a disease116. 
Approximately fifty different biochemical processes occur exclusively within a peroxisome. 
Some of the reactions are anabolic i.e. constructive, resulting in the synthesis of essential 
biochemical compounds including bile acids, cholesterol, plasmalogens (phospholipid 
analogues), and docosahexanoic acid (DHA), which is a long chain fatty acid that is a 
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component of complex lipids, including the membranes of central nervous system. Other 
reactions are catabolic i.e. destructive and lead to the lysis of some fatty acids, via β-
oxidation including very long chain fatty acids117-119.  
Peroxisomes contain several oxidative enzymes, which generate H2O2 as a by-product of 
their reactions. This highly poisonous reactive oxygen species (ROS) is rapidly converted to 
H2O through the action of peroxisomal catalase, at least under most circumstances. A 
number of degenerative diseases are linked to ROS induced alternation in cellular 
functions120. The reactions are catalyzed by appropriate FAD-linked enzyme: a) urate 
oxidase, b) xanthine oxidase, and c) L- and D- amino acid oxidases. Flavin oxidases reduce 
oxygen to H2O2, which is then decomposed by catalase121. However the peroxisomal 
pathway differs from that of the mitochondria in several important respects122.   
β –oxidation pathway similar to that of mitochondria is present in peroxisomes and the 
process is carried out by two distinct groups of enzymes. The classical first group utilizes 
straight chain saturated fatty acyl-CoA as substrates, whereas the second group acts on the 
branched chain acyl-CoA119, 124.   
Severe effects of peroxisomal dysfunction, which secondarily leads to several human and 
animal diseases, emphasize the importance of peroxisomes for survival. Depending on the 
specific defect, clinical manifestations range from the mild to the fatal.  
There are about 25 peroxisomal disorders known, although the number of diseases that are 
considered to be separate, distinct peroxisomal disorder varies among the researchers and 
health practitioners125, 126. Peroxisomal disorders are subdivided into two major categories.  
The first category is the disorders resulting from a defect in a single peroxisomal enzyme127. 
These disorders include hyperoxaluria type I (alanine: glyoxylate aminotransferase), 
Refsum’s disease (phytanoyl-CoA hydroxylase), X-linked adreno-leukodystrophy (ALDP), 
rhizomelic condrodysplasia punctata (RCDP) types II and III (dihydroxyacetone phosphate 
acyl transferase), and the β-oxidation disorders (acyl CoA-oxidase, bifunctional protein, and 
thiolase). These disorders result from a deficiency in only a single enzyme of the 
peroxisome, and therefore generally only affect a single peroxisomal metabolic pathway.  
Conversely, there is also a set of disorders which results from a malfunction to form intact, 
normal peroxisomes, resulting in multiple metabolic abnormalities, which are referred to as 
peroxisome biogenesis disorders (PBD) or as generalized peroxisomal disorders128 and 
include the Zellweger syndrome (ZS), Neonatal adrenoleukodystrophy (NALD), Infantile 
Refsum disease (IRD). Rhizomelic chondrodysplasia punctata (RCPD) type I. 
Several proteins have been identified which play a role in the degradation of peroxisomes129-
133. There are a number of reports in the literature describing the histology of the liver, 
spleen. and lymphoid organs of VL, during human disease and experimental infection134-136. 
In an experimental model of VL in golden hamsters, histopathological analysis showed137 
dissemination of the parasite mainly to liver & spleen. The former organ showed 
hypertrophy and hyperplasia of Kupffer cells with focal areas of inflammatory infiltration in 
nodular pattern. Gross examination of the liver indicated hepatomegaly. The spleen 
disclosed intense proliferation and enlargement of mononuclear phagocytic cells, revealing 
nodular configuration. 
Both biochemical and morphological changes that take place in host peroxisomes during 
Leishmania infection, was detected 138, 139 pointing to the occurrence of a peroxisomal disorder 
during this parasitic disease. Liver peroxisomes were found to be functionally defective when 
purified after L. donovani infection. The activities of key enzymes catalase, urate oxidase, 
dihydroxy acetyl phosphate acyl transferase (DHAPAT) and superoxide dismutase (SOD) 
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were either deficient or could not be detected after parasite infection. H2O2 producing 
peroxisomal β-oxidation was significantly elevated after 90 days of infection, with concomitant 
induction of superoxide radical production. Proteolytic activity in infected liver peroxisome 
was found to be inhibited, pointing to possible uneven processing of peroxisomal proteins. 
The morphology of peroxisomes after Leishmania infection was impaired. The evidence 
obtained for Leishmania-induced peroxisomal dysfunction may provide clues to develop new 
drugs against this parasite, capable of protecting normal function of this ubiquitous host 
organelle for successful treatment. Calcium is known to be stored in mitochondria and 
endoplasmic reticulum and is mobilized by second messengers140, 141. As one of the vital 
organelles of eukaryotic system, role of peroxisomes in mobilizing calcium has recently been 
explored in which peroxisome was identified as a calcium-containing intracellular organelle 
for its possible candidacy as one of the mediators towards cell signaling142. 
Immense interest has recently been developed to study peroxisomal properties in more 
details due to involvement of this mammalian microbody in normal cellular function140. It 
has already been reported that infection due to Leishmania pathogen leads to host 
peroxosomal damage108. As peroxisome is known to be involved in various metabolic 
pathways to monitor normal function of the host cells109, it is essential that Leishmania-
induced dysfunction of this organelle should totally be repaired during treatment of VL. 
Moreover, a group of human diseases can occur when peroxisomal properties are impaired7. 
It may lead to genetic disorder resulting in various other complications143, 144. It is thus 
logical to investigate whether treatment of this parasite-borne disease with the existing 
drugs can reverse peroxisomal defects developed due to Leishmania infection to avoid post 
therapeutic problems111  which may occur due to unavailability of specific non toxic drugs 
against this pathogenic disease. In the present work it has been clearly shown that 
resumption of normal peroxisomal function could not be attained when one of the existing 
drugs SAG 112 was used for chemotherapy against VL. 
2. Materials and methods 
2.1 Materials 
All the reagents except fetal calf serum (FCS), Medium-199 and sodium antimony gluconate 
(SAG) were purchased from Sigma Chemicals, USA. Fetal calf serum and Medium-199 were 
obtained from Gibco BRL, USA. SAG was procured from GlaxoSmithKline, UK. 
L. donovani strain MHOM/IN/AG/83 was obtained from Indian kala-azar patient145 and 
maintained by intracardial passage every 8 weeks in Syrian golden hamsters. Promastigotes 
were obtained by transforming amastigotes isolated from infected spleen146 and maintained 
in medium- 199 supplemented with 10% fetal calf serum in vitro. 
2.2 In vivo study with SAG in L. donovani infected hamsters 
Syrian Golden hamsters (4 weeks old weighing 50-65 gm) were infected individually with 
freshly purified L. donovani amastigotes through cardiac route. After 30 days of infection the 
animals were treated with SAG (30 mg/kg body weight). Each hamster received 
intramuscular injections of the drugs every alternate date for 15 days. The compound was 
dissolved in DMSO. The final concentration of DMSO was < 0.1% (v/v). Infected hamsters 
in the control group received 200ml of 0.1% DMSO per animal intramuscularly. Animals of 
all groups were sacrificed two month after administration of last treatment. The splenic 
parasite burden was determined from impressions smears after Giemsa staining147. Total 
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parasite burden was calculated from the following formula—organ weight (mg) x number 
of amastigotes per cell nucleus x (2 x 105) All animal experiments were approved by the 
local body of our institute’s animal ethics committee. 
2.3 Isolation of Hamster liver peroxisomes 
Peroxisomes from normal and infected liver were purified according to the procedure already 
reported148. Hamster liver was dissected out to homogenize with buffer at 4 °C containing 0.25 
M sucrose, 10 mM TES of pH 7.5, 1 mM EDTA, 0.4 mM phenylmethylsulfonyl fluoride, 0.2 
mM leupeptin and 0.1% ethanol. Light mitochondrial fraction from the homogenate was 
separated by differential centrifugation and then suspended in the same TES-EDTA buffer 
mentioned above at the 1:1 ratio of liver weight to buffer. 30% Nycodenz (w/v) was prepared 
in a buffer of pH 7.5 that contained 10 mM TES and 1 mM EDTA. 2 ml of the light 
mitochondrial suspension was layered over 10 ml of freshly prepared nycodenz solution and 
centrifuged at 105000×g for 50 min in a Sorvall-ultra 80 ultracentrifuge using T-865 fixed angle 
rotor. After centrifugation the interfacial materials were aspirated off to obtain pelleted 
peroxisome which was separated at the bottom of the centrifuge tube. Purified peroxisomes 
were then suspended in a minimum volume of homogenizing buffer to store at -20 °C. 
2.4 Western blot analysis 
Peroxisomal proteins were separated by a 10% SDS–PAGE149 followed by affinity transfer 
blotting using nitrocellulose paper150 . 
2.5 Activity staining for SOD 
Peroxisomal SOD was separated on a 10% nondenaturing polyacrylamide gel149 for activity 
staining151. Gels were incubated in solution A (20 mg Nitro Blue Tetrazolium in 10 ml glass 
distilled water) for 20 min, then in solution B (4mg Riboflavin, 0.4 gm K2HPO4 and 600 µl 
TEMED in 50 ml glass distilled water, pH 7.8) for another 20 min and finally illuminated 
until white bands appeared on a blue background 
2.6 Assay of enzymes  
Catalase activity was determined by monitoring the decomposition of H2O2 at 240 nm152. 
SOD activity was assayed by determining ability of this enzyme to inhibit pyrogallol 
autoxidation rate153. The assay mixture contained 0.2mMpyrogallol in air-equilibrated 
50mMTris–cacodylic acid buffer, pH 8.2, and 1mM ethylenediaminetetraacetic acid. Rate of 
autoxidation was obtained by monitoring the increase in absorbance at 420 nm in a Hitachi 
spectrophotometer, No U2000. SOD has the ability to inhibit autoxidation and the extent of 
inhibition is taken as the measure of enzymic activity. Protein was determined using Folin 
and Ciocalteu’s phenol reagent154 . 
2.7 Electron microscopy 
Peroxisomes were fixed, processed to embed in Spur medium155  to cut thin sections, and 
then stained to examine under an electron microscope (Hitachi-H600) at 75KV. 
2.8 Immunofluorescence 
Peroxisomess were fixed with formaldehyde in PBS for 15min, permeabilized 0.3% Triton X-
100 in PBS for 5min, and then blocked with 3% bovine serum albumin in PBS for 30min. 
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were first incubated with appropriate primary antibodies (1: 100) for 30min followed by 
Alexa 633 coupled secondary antibody (1:100) for another 30min and then examined under 
TCS-SP Leica confocal microscope having krypton–argon mixed-laser facility. 
2.9 Statistical analysis 
Statistical analyses were conducted through Student’s t-test as described156  
3. Results 
3.1 Effect of SAG on Leishmania infected hamsters macrophages 
Following 30 days of L. donovani infection the animals were treated SAG at a dose of 30 
mg/kg body weight, dissolved in DMSO, and the splenic parasite burden was determined 
after two months of the last dose given as described in materials and methods. In case of the 
SAG treated animals, no parasite was detected (data not shown).  
3.2 Electron microscopic study of Peroxisomes after SAG treatment 
Peroxisomes were isolated from normal, Leishmania infected as well as cured SAG treated 
hamster livers and processed for electron microscopic studies. In case of normal 
peroxisomes, electron dense core was observed inside the matrix and the average diameter 
was found to be 0.37 µm (Figure 1A). But peroxisomes isolated after infection were found to 
be swollen with severe membrane distortion, and the electron core became scattered, and a 
few of them had no core inside. The average diameter of the swollen organelle was 
determined to be 0.82 µm (Figure 1B). Peroxisomes obtained after SAG treatment showed 
interesting results. The membranes were no more distorted and the organelles were reduced 
almost to their normal size. The average diameter was found to be 0.4 µm (Figure 1C). But in 
most of the organelles, the dense electron core inside the matrix was not detected. 
 
 
Fig. 1. Electron micrograph of hamster liver peroxisomes (x 50,000). Peroxisomes  after pre- 
and post-fixation with 6% gluteraldehyde and 1% osmium tetroxide were examined under 
Hitachi electron microscope at 75 KV. A. Normal Peroxisomes, B. Peroxisomes post 90 days 
infection, C. post SAG treatment 
3.3 Assay of peroxisomal enzymes before and after SAG treatment 
Peroxisomal marker enzyme catalase was assayed in peroxisomes isolated from normal, L. 
donovani infected as well as cured animal livers after SAG treatment. Specific activity of 
Catalase is known to be diminished during Leishmania infection157 and the same was obtaiuned 
in this case (Table 1), but catalase activity was not restored back in peroxisomes obtained from 
SAG treated cured hamsters (Table 1). Activity of another important peroxisomal enzyme SOD 
was also not detected in case of peroxisomes isolated after SAG treatment (Table 1). 
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Enzyme Specific Activity (unit/mg protein) Normal Infected  SAG Treated 
Catalase 3373 1884 1763 
 SOD 3.2 ND ND 
Table 1. Enzyme activities in normal peroxisome, peroxisome after 90 days infection and   
peroxisomes after post SAG treatment. Results are in mean + S.D. for three different 
experiments 
3.4 Protein profiles of peroxisomes 
Figure 2 indicates that the peroxisomal protein profiles of normal, infected and SAG treated 
cured hamsters livers were different when subjected to SDS-PAGE. Densitometric scanning 
pointed to three distinct protein bands of Mr 104.5, 80.6 and 50.4, although when found to 
be present in peroxisomes after infection and after SAG treatment, they could not be 
detected in normal peroxisomes. Significant differences were also observed for the protein 
bands of Mr 30.2, 28.0, 20.9, 10.3 and 9.7 (Figure 2).  
 
 
Fig. 2. SDS-PAGE analysis of peroxisome prepared from normal hamster liver (Lane 1), 
hamster liver infected with Leishmania parasite for 90 days (Lane 2),  post SAG treatment 
(Lane 3). 40 μg protein  samples were run on 10% polyacrylamide gel 
The same PAGE when subjected to Western Blotting and probed with anti Cu-Zn SOD to 
find out the presence of SOD in the organelles isolated at various conditions, showed that 
SOD was not detected in peroxisomes obtained infected as well as SAG treated cured 
hamsters (Figure 3). 
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Fig. 3. Western blot analysis of glycosomal proteins. Peroxisomes were subjected to SDS  
PAGE for separation of proteins, transferred to nitrocellulose, and then incubated With 
antibody against Cu- Zn SOD. Normal peroxisomes (Lane 1), peroxisomes post 90 days 
infection (Lane 2), peroxisomes post SAG treatment 
3.5 Impact on SOD activity 
Activity staining of native polyacrylamide gels clearly showed that SOD activity of infected 
and SAG treated peroxisomes was totally lost (Figure 4). 
In a separate experiment, presence of SOD was examined using anti Cu-Zn SOD under 
confocal microscope. SOD was not detected in infected (Figure 5B) as well as in SAG treated 
(Figure 5C) hamster liver peroxisomes. Normal peroxisomes were used as positive controls 
(Figure 5A). 
4. Discussion 
Peroxisomes are abundant in host reticuloendothelial cells158. The role and importance of 
peroxisomes in a wide variety of metabolic pathways, including longchain fatty acid β-
oxidation, ether-linked glycerolipid biosynthesis, and H2O2-based respiration, have been 
thoroughly studied159-161. The importance of fatty acid β-oxidation for the survival of 
microorganisms in other parasitic and fungal diseases has already been documented162-164. 
Hamster liver peroxisomes are found to be severely damaged, both morphologically and 
bichemically, during Leishmania infection157. The structure and function of this host organelle 
are reported to be highly affected by the parasitic attack. The pentavalent antimonial 
compound SAG are widely used as first-line chemotherapeutic165, 166 agents against all forms 
of leishmaniasis including visceral leishmaniasis167, 168. In this work, we have assessed the 
status of host liver peroxisomes after the complete treatment of the L. donovani infected 
animals with standard dose of SAG. 
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Fig. 4. Activity staining of SOD after conducting non denaturing PAGE. Staining was carried 
out according to the procedure described under Materials and methods Normal 
peroxisomes (Lane 1), peroxisomes post 90 days infection (Lane 2), peroxisomes post  SAG 
treatment (Lane 3) 
 
 
Fig. 5. Confocal microscopy of Normal Peroxisomes After treatment anti Cu-Zn SOD  
peroxisomes  were examined under a Leica DM IRB inverted microscope. Normal 
peroxisomes (Set A), peroxisomes post 90 days infection (Set B), peroxisomes post  SAG 
treatment (Set C) 
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Peroxisomes were isolated by standard procedure148  from normal hamters, also from 
animals after Leishmania infection and from hosts after complete cure of the parasitic disease 
using conventional SAG treatment169,170. When parasite burden was measured two months 
after administration of the last dose, no parasite was detected in hamster spleen or liver, and 
that gave indication towards the complete cure of the disease. 
The diameter of normal peroxisome is known to vary between 0.5 to 1.0 µm in animal 
tissues171, 172. However, the average diameter of hamster liver peroxisome was found to be 
0.37 µm. As evidenced by electron microscopic examination the morphology of the 
peroxisomes after parasite infection was found to be different. Membrane structure was 
damaged and the dense electron matrix172 was unevenly distributed, with the appearance of 
dark patches having an average diameter of 0.82 µm. The presence of large peroxisomes 
suggests the swelling of these organelles during infection. But the average diameter of 
peroxisomes isolated from hamsters after SAG treatment was determined to be 0.4 µm, 
which is quite similar to that of the normal organelles, indication that damaged peroxisomes 
are morphologically repaired after SAG treatment. 
On the other hand, the key peroxisomal enzyme catalase173, 174, 175 was found to be less active 
after host-parasite interaction. But when catalase activity was examined in SAG treated 
hamster liver peroxisomes, it was found that the enzyme activity was not restored back, 
even after complete cure of the parasitic disease, indicating that the peroxisomes are 
biochemically not repaired after SAG treatment. 
SOD is one of the key enzymes of oxygen defense system. It is known to be an essential 
factor in mediating normal cellular functions176, 177. It is already reported that peroxisomal 
SOD activity is not detected after Leishmania infection157. In this study, the results clearly 
revealed that this essential enzyme is absent even in the peroxisomes isolated from hamster 
livers, after SAG treatment. In a separate experiment, Western Blot analysis showed no band 
for SOD in case SAG treated host liver peroxisomes. Activity staining of native 
polyacrylamide gels also showed that activity of peroxisomal SOD, was lost completely after 
parasitic disease, and could not be detected after SAG treatment. Confocal microscopic 
studies also revealed the same results, indicating that peroxisomal SOD activity was not 
restored back post SAG therapy. 
Difference in protein profile in peroxisomes isolated from normal, infected as well as SAG 
treated hamster livers also indicate towards the status of peroxisomes. Some distinct bands 
were found in the infected and SAG treated peroxisomes, but were absent in normal 
peroxisomes. During Leishmania infection, some proteins get damaged and also proteolytic 
cleavage takes place, as result, more bands were obtained in infected peroxisomes157. The 
similarity in protein profiles between infected and SAG treated peroxisomes reveled that the 
biochemical properties of peroxisomes are not restored properly after SAG treatment. 
Considering the knowledge we have gathered from the present work, it is clearly 
established that the peroxisomes, that get damaged during Leishmania infection are 
morphologically repaired after treatment with a common antileishmanial afent SAG, but the 
biochemical properties are not restored back. 
PKDL  is a common problem178, 179 in kala azar patients but the actual reason behind the 
occurence of this disease is not yet known. Several peroxiomal disordes like ZS, IRD  etc are 
also reported.  Treatment with a common drug SAG, could repair the morphology of the 
distorted peroxisomes but the biochemical properties are not restored180.  
We propose that the peroxisomal defects caused by infection of the parasite Leishmania 
donovani lead to induce symptoms similar to genetic defects in the biogenesis of 
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peroxisomes.  Although there is no authentic evidence available at this time, defective 
peroxisomes may also be the root to crop up PKDL in post kala-azar patients. Extensive 
investigations are still needed to sort out various unresolved problems in these areas to 
provide clues for new drug development against leishmaniasis. Present research in our 
laboratory is oriented towards this direction. 
5. Conclusion 
VL is a deadly disease of viscera caused by the parasite Leishmania donovani and also known 
as kaka-azar.  The internal organs particularly liver, spleen, bone marrow and lymph nodes 
are attacked when the parasitic protozoa is transmitted to humans by infected female sand 
fly bites. People of Mediterranean and adjacent countries are attacked with this pathogen in 
the form of flagellated promastigotes. However, aflagellated amastigotes are found inside 
and outside of the affected reticuloendothelial cells. 
At this time there is no definite antileishmania agent which may be used confidently to treat 
VL for a permanent cure. Drugs of choice available in the market, are being taken up 
selectively by trial and error methods.  Most of them are too toxic to cause severe secondary 
infections and at the same time very costly to afford.  Moreover, drug resistance is one of the 
acute problems to provide guarantee for a complete cure of VL. As a result there is an 
urgent need to explore for new drug development against this parasitic disease which is 
lethal, if untreated. 
While exploring our attempts to identify an authentic chemotherapeutic agent against VL 
we also took into account the occurrence of PKDL. There are reports to believe that cured 
kala-azar patients as certified by the physicians, are susceptible to return for the treatment of 
PKDL.  
Cause of PKDL is still not known.  It is possible that the said pathogenic disease is occurred 
due to continued impaired function of the internal host organs even after treatment with 
commonly found drugs. We have shown that host liver peroxisomal properties are impaired 
due to the attack by Leishmania pathogen. We have also reported that the affected 
peroxisomes are not repaired after adequate treatment with the existing drugs. Treated 
animals with deficiency in peroxisomal properties also do not survive for a long time. 
It is known that that peroxisomal defects lead to various genetic disorders.  It is still not 
known whether in treated patients of VL who are likely to carry peroxisomal deficiencies 
even after traditional treatments, symptoms similar to genetic defects in the biogenesis of 
peroxisomes are developed.       
A novel chemotherapeutic agent has been discovered in our laboratory to prove that this 
antileishmania agent has the ability to repair peroxisomal damage which takes place due to 
attack by VL. This finding may lead to provide effective clues to develop new and more 
potent drugs to stop recurrence of this pathogenic disease in other forms including chance 
to trigger symptoms develop due to  peroxisomal disorder. 
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